DAX-0,72 % EUR/USD+0,24 % Gold+1,41 % Öl (Brent)-1,81 %

Mannkind, Game-Chancer in Sachen Diabetik? (Seite 541)

WKN: A2DMZL | Symbol: MNKD
-1,29 %
-0,015 USD

Begriffe und/oder Benutzer


Patience For Patients – Our Latest Thoughts on MannKind (MNKD) 5/31/19
May 31, 2019

*** The following is a complete copy of the raw text from Issue #292 of Nate’s Notes, which was published for subscribers on May 17th, 2019, and reflects our opinions of the market and all stocks mentioned as of that date. The full issue (which includes all of the tables and charts referenced in the text-only version below) can be downloaded as a .pdf by clicking the image to left. ***

Nine mile skid on a ten mile ride,
Hot as a pistol, but cool inside…

– from He’s Gone (Garcia/Hunter)

Patience… Patients… (then more and more patients…)

Though I have to admit I am not am not terribly thrilled by the fact that the markets have taken a sharp turn for the worse in the two weeks or so since the Inter-Issue Commentary came out, I also have to admit that a) I have been waiting for an honest-to-goodness pullback so we could see how the market handles it (and we’re about to find out), and b) all five of the indices I use to gauge the health of the overall market (see “Eyebrow Levels” table) are still flashing “bull market” signals for us; consequently, I am not making many changes to the newsletter’s Portfolios this month (see below for commentary on the rationale behind the ones I am making).

Last MannKind Update For Awhile (thanks for your patience!)

As promised, I am using this month’s issue to take a look at where things stand with regards to script counts for Afrezza (among other things) in order to make a plan for our position going forward, and, as you will see while working your way through the commentary below, barring the release of some game-changing news in the months and quarters ahead, I am optimistic that this will be the last issue in which I will need to spend time “dissecting” the MannKind situation (beyond the usual “company write-up” each month, of course) as part of helping subscribers navigate what has truly been the most exceptional story I have ever seen play out in my 30+ years of following the biotech sector!

That being said, while there are plenty of facets (and sub-facets!) of the story that could be explored during a “check-in” like this, due to space constraints (one last time, knock on wood!), I have narrowed the list down to the handful of topics that I feel are most relevant, and, in order to cover as much ground as possible, I am also going to share thoughts in a slightly more bullet-pointed fashion than usual as part of getting the train back on the tracks in one fell swoop when it comes treating MannKind as a typical stock in the newsletter rather than the atypical one that it has become over the past few years (see “Social Media…” below).

Script Counts – Though the numbers that everyone is watching on social media have a fair amount of uncertainty and “fuzziness” associated with them thanks to the manner which in the data is gathered, as long as the companies gathering the data keep their algorithms and data collection methods constant, these numbers can still be useful for spotting trends, as well as for giving observers a “scale” of some sort against which to measure progress… and, though the numbers that have been reported over the past several weeks are admittedly coming in at the very low-end of the range I was hoping to see them in by the time the May issue went to press, the bottom line is that, at least as measured by the stick given to us by the reporting agencies, Afrezza is now consistently generating $1 million per week in revenues (a dollar amount that was still taking the company a month to achieve less than 24 months ago).

Yes, I was hoping to see it inching up closer to the $1.2-$1.4 million range by this point in time, but $1 million per week was my “must see” number… and since we’ve been getting it, I see no reason to change our outlook at this point in time.

That being said, the August issue will likely be the next time I plan on using space in the newsletter to take anything more than just a cursory look at the script counts as a metric against which to consider lightening up our position, and you are encouraged to keep this in mind as you evaluate your own plans for the stock – if you are comfortable waiting until then for me to check-in again on the matter, you probably own “the right amount” of stock; however, if the idea of having to wait until August for me to revisit the topic seems crazy (or uncomfortable) to you, it may mean that you own more stock that you can sleep with comfortably at night, and though the decision will ultimately be yours to make, I would encourage you to at least think about selling a portion of your position and moving it into some of the other stocks that are firing on all cylinders but seem have fewer headwinds blowing against them at this stage of the game (Catasys is another company that may be gearing up to see exponential growth over the next 36 months and may be worth a look, for example).

Social Media, Financing, Dilution, etc. – As time has gone by and other bulls have given up on the stock, it seems that I have, for better or worse, become “the last man standing” on the bullish side of the ring, and, as a result, whenever new bearish articles get written, folks in growing numbers have been turning to me to see what I have to say… and since my number one goal has always been to help my subscribers feel as comfortable as possible about investing in the stocks I have recommended to them, I have been willing to utilize space in my newsletter to provide an alternative point of view to what has become a never-ending onslaught of negative articles about the stock and its prospects over the past several years.

For example, as those of you who have been in the stock for awhile now know all too well, ever since MannKind got the rights to Afrezza back from Sanofi in early 2016, folks with a negative bias regarding the story have been writing articles warning investors that “if the company runs out of money, it will be bad for shareholders!” (as if this is a problem unique to MannKind, eh?) without ever pointing out that the odds of such a thing happening for a company in MannKind’s situation were/are actually quite small…

…and while it would not surprise me at all to see those bloggers who either don’t know better or are intentionally trying to create fear, uncertainty, and doubt (“FUD,” if you’re new to social media) around the story continue writing such articles until the company finally turns profitable, this is another topic that I am done taking up space to discuss – perhaps there was a chance the company would have declared bankruptcy as part of a “clearing the decks” process when Castagna took over, but that isn’t the route he took, and now that the relationship with Deerfield is about to enter a new chapter, I believe the odds of MannKind declaring bankruptcy are even lower than they were last summer (and, if you recall, I was pointing out they were already “extremely low” a year ago).

Of course, the second half of the warning from these bloggers is also always some variation of “and the only way the company will avoid running out of money is if they sell more shares” (i.e. “dilute” the stock)… and, while there is no denying the fact that “dilution is dilution,” as you have also heard me say many times over the years, there is a big difference between dilution when it comes to a retail apparel company trying to boost sales and dilution when it comes to a biotech company on the verge of finding success with its lead product (especially if its lead product happens to have blockbuster potential in the categories in which it competes).

The simple reason for this is that while “one more round of financing” isn’t likely to result in much of an increase in sales for a cool line of hawaiian shirts (you just can’t increase global demand for a line of shirt prints 50-fold with “a few tens of million dollars more in advertising,” for example), such a “small” sum of money can (and often does!) prove to be the final catalyst required to help a new drug finally hit critical mass and grow from almost nothing to a billion dollars (or more!) in sales in a very short period of time.

And, as a side note (since I get asked about it often often), after spending the first ten years of my career thinking I was adding value by building financial models for the up-and-coming biotech companies I followed at the time… only to discover time and time again that once a company’s lead product finally hit critical mass, not just my models, but the the models of just about all the other analysts as well, no longer worked (i.e. the companies would start to beat our estimates by wide margins quarter after quarter, and all the models had to be re-calibrated for a whole new set of assumptions that took into account the new realities around the drug and its new rate of acceptance in the marketplace)… I finally came to accept the fact that it is this unique “transformative growth phase” of biotech stocks that makes them such poor candidates for traditional financial modeling.

Summarizing this section, I do not believe the company will run out of money, and I do not believe you need to be as worried about dilution as some would like you to be*… but if either of these possibilities concern you, you are naturally encouraged to sell enough stock that you are no longer worried about them.

*as a first-hand example, though Celgene’s success clearly does not guarantee MannKind’s, please keep in mind that subscribers who got involved with Celgene when it was first recommended in the newsletter in 1995 went on see their initial shares diluted by half… and then those shares were diluted by half again as more time went by (i.e. the original shares eventually only controlled one-fourth of what they used to!)… but despite (“because of,” really) all of the dilution along the way, I’m sure that everyone who has enjoyed the run from 44 cents back then to today’s closing price of $95.42 is quite content with the gains they finally experienced once thalidomide finally caught on with the medical community – dilution really is par for the course (and perhaps even a requirement?) when it comes to biotech stocks that are on the path to greatness, so please be wary of anyone who tries to convince you otherwise (especially since I am done rehashing this debate, both in the newsletter and online as well).

Management – As discussed before, as time has gone by and Afrezza has proven itself to be everything we hoped it would be when we first got involved with the story back in 2009 (i.e. it has turned from an “unknown” into a “known” variable), “management” has essentially become the last remaining piece of uncertainty surrounding the story; unfortunately (and especially given where we are at in the story), I think it is still far too early to know one way or the other whether the folks calling the shots will find success… and, as is always the case with any investment, all we can do is make a decision about whether or not we think management has a reasonable game plan and then adjust our portfolios accordingly.

For the time being, I am very much looking forward to seeing what happens with scripts over the next six months, as well as finding out what (if anything) might change once the company’s final payment to Deerfield has been made in July (a turn of events that will almost certainly give MannKind a much greater degree of flexibility on many fronts), and so, again, this is another topic that I am going sign-off on for awhile by saying that, at least for now, I do not see enough evidence to conclude that what’s been going on behind the scenes since Castagna took over as CEO is not going to lead to fruition… but, again, if you feel otherwise, you are encouraged to reallocate some of your MannKind into other positions when it seems appropriate to you do so (and, yes, I will be happy to reflect on the topic of “management” again when the August issue rolls around, if needed).

Short Interest – Though your guess is as good as mine as to who would choose to still be short the stock at these prices (and why), what we do know is that if it is essentially the same group of short sellers that has been behind the relentless shorting of stock over the years (i.e. they have been “averaging down” every step of the way), they ought to have an average cost basis of somewhere in the $2.50-$4 range at this stage of the game (for reference, our Model and Aggressive Portfolios are in the stock at an average price of $2.48 and $2.76, respectively, by taking the other side of that trade on an almost monthly basis for years now), and, if this is the case, the price at which the short position will collectively start to lose money (and, as part of that process, perhaps start thinking about covering) is most likely somewhere in that range as well.

On the other hand, if a lot of the “original” shorts in the stock have actually turned their paper profits into real profits over the past few years by handing the short position off to other less-sophisticated short sellers (this, by the way, is an alternative explanation that “works” to explain why there is a never ending supply of negative press for the stock – it’s not so much to scare out retail longs as it is to suck in new retail shorts so that the big fish can cash out… and, of course, in reality, it is probably a bit of both), it means that the point at which the position will collectively turn unprofitable (and, in doing so, start triggering margin calls for a far less sophisticated group of investors) is perhaps even lower.

In either case, even if you decide that you are going to completely exit your MannKind position, I want to encourage you to move that money into other long positions rather than trying to short MannKind at current prices, as it has become one of the most overcrowded (and least attractive from a risk-reward basis – see commentary below) trades I’ve ever seen develop in the sector.

Outlook – If there is one thing that time has taught me more than anything else when it comes to the stock market, it is that you don’t buy biotech companies (especially ones still in the early stages of commercializing their first drug) based on their current sales, next quarter’s sales, or even next year’s sales… you buy them for where you think they will be 5-10 years from now if your assessment of their potential turns out to be correct (and the bigger the difference between today’s valuation and the potential valuation “down the road a ways,” the more attractive the opportunity); if MNKD were trading at a $2 billion market cap, it might be trickier to know what to do with our position, but with a market cap of less than $250 million (a circumstance brought on by a very zealous band of short sellers who will eventually need to unwind their positions, mind you), it is not difficult at all to realize there is far more upside potential than downside risk in the stock at current prices (and, to be honest, not a lot will have to go right in the environment of anger, frustration, and fear that has been created around the stock these days in order for that potential to start being unlocked).

Though the next six months may prove me wrong, based on what I am seeing and hearing, it appears to me that Afrezza has almost certainly achieved enough critical mass on the awareness front that it is not going to go away… and this means that the biggest question mark for us as investors is whether it will remain an asset that is 100% controlled by MannKind, “shared” by MannKind (via partnership and/or licensing agreements), or sold outright to another entity.

Of course, as discussed in previous issues, all of these outcomes will likely count as “wins” for all but the most bitter and stubborn of shareholders, and so, provided you have taken care to only own as many shares as you can truly sleep with comfortably at night, you are encouraged to remain patient with your position while we wait to see what the next six months bring.

That being said, please note that while I am buying the stock in the Model this month, I am also selling a little less than 5% of our intentionally very large position in the Aggressive Portfolio and moving that money into the likes of Catasys and Disney in order to help drive home the point that it really is ok to sell some of your MannKind (if you choose to) and move it into other ideas!

Top Picks (for new money this month)

All else being equal (i.e. you already own “pretty much everything” in the newsletter), my top picks for you this month are:

Catasys (CATS) – Catasys’ stock is once again tracing out the most bullish looking chart pattern of all the stocks in the newsletter, and though it can be emotionally challenging to buy stocks that are hitting new highs on a regular basis, these are often the very sorts of situations that are supposed to be bought (especially when they are being bought in small lots on a regular basis… which, of course, is exactly what we try to do in the newsletter!).

MannKind (MNKD) – As discussed elsewhere in this month’s issue, I continue to believe there is a huge disconnect between the company’s current market cap and the true value of its assets… and given how the pieces are lining up, it may not be much longer before that gap finally starts to disappear.

Walt Disney (DIS) – A great chart pattern being traced out here as well, with the “bonus” being that not only is Disney firing on all cylinders as a company these days, its stock has held up very well despite its obvious exposure to a potential slowdown in the global economy (i.e. there seem to be a lot of buyers in the market these days!).

Outstanding Orders

For the reasons discussed above and below, the Model (Aggressive) Portfolio will sell 550 (2,000) Luminex, (100,000) MannKind, and 251.8 (672.8) Tekla Life Sciences and will purchase 1,000 (5,000) Catasys, 100 (300) Celgene, 50 Electronic Arts, 100 First Solar, 10,000 MannKind, and 100 (250) Walt Disney. We will use the closing prices on Monday, May 20th, for all transactions.

Summary of Recommended Stocks

AdvisorShares Ranger Equity Bear ETF

Though it is clearly a case of the market wagging HDGE and not the other way around (so we can’t read too much into it), the huge surge in volume we have seen in HDGE over the past few weeks would definitely count as a “bullish” clue if it was an actual stock that we were hoping to go long with… and though it is still far too early to declare that a new uptrend is getting underway, I believe there is some value to be gained by keeping an eye on this “short ETF” even if you do not own any. And, speaking of which, I want to remind you that this ETF is in the newsletter solely for the most aggressive traders among my subscriber base, and most of you do NOT need to own it. HDGE is a strong buy under $7 and a buy under $9.


As you can see in the chart to the left, though Apple’s stock initially responded quite nicely to the company’s earning report at the end of April, thanks in part, no doubt, to the saber rattling that is going on between the U.S. and China, I am afraid that the stock has done nothing but slide since then. For its second fiscal quarter, Apple reported revenues of $58.0 billion and net income of $2.2 billion, or $2.46 per share, as compared to revenues of $61.1 billion and net incomes of $2.3 billion, or $2.73 per share, in the same period a year ago. Though the stock may fall further if the market remains weak, I remain comfortable with the company’s long-term prospects, and AAPL is now a strong buy under $175 and a buy under $200.


As you can see in the chart to the right, Catasys’ stock appears to breaking out nicely to the upside in response continued progress with the company’s business model, as well as a great earnings call by management a little over a week ago. For its first quarter, Catasys reported revenues of $6.8 million and a net loss of $2.9 million, or $0.18 per share, as compared to revenues of $1.9 million and a net loss of $4.2 million, or $0.27 per share, in last year’s first quarter. The company appears poised to begin adding clients at an accelerating clip, and though I am very optimistic about the future, I want to caution you to not “chase” the stock – “small purchases regularly”! CATS is now a strong buy under $14 and a buy under $22.


Not surprisingly, Celgene’s has continued to creep higher in anticipation of the company’s merger with Bristol-Myers Squibb (BMY – $46.85) later this year, though, as you can see if you do some quick math in your head, the stock is still trading at a slight discount to the “true” (but always varying, based on the price of BMY… and ignoring the “wild card” of the CRVs associated with the deal) value of the transaction. Though there is probably not a lot of near-term upside in the stock, as you’ll see below, given the weakness we have been seeing in LMNX and HQL lately, I am moving a bit of that “biotech money” into Celgene as a “safe haven” play ahead of the merger. CELG is a strong buy under $90 and a buy under $98.

Cirrus Logic

Yipes! As you can see in the chart to the right, after spending the past few months gradually working its way higher in exactly the sort of slow-but-steady fashion we like to see, Cirrus’ stock (along with many other chip stocks) suddenly reversed course and now appears to be in free fall in response to the shifting winds on the trade war front (surprise, surprise). As you know, we have been very underweighted in pretty much all of our chip positions for awhile now, and though I may be tempted to start buying them more aggressively if they are able to find some solid support by the time next month’s issue goes to press, for now I’d rather buy other stocks that are acting better. CRUS is a strong buy under $36 and a buy under $42.


While it remains to be seen where the stock will head next, I would love to see it simply trade sideways for another several weeks, as it appears that there is some nice consolidation happening here in the $10-range… and, as you’ve heard me say before, the longer a stock trades sideways before it finally breaks out, the more powerful the move ends up being as time goes by. For the company’s first quarter, Cleveland-Cliffs reported revenues of $157.0 million and a net loss of $22.1 million, or $0.08 per share, as compared to revenues of $180.0 million and a net loss of $84.3 million, or $0.29 per share) in the same period a year ago. With a reminder that there is no rush, CLF is strong buy under $9 and a buy under $12.

Electronic Arts

And, speaking of bases, though the tumble the stock took in the second half of 2018 was a painful one, indeed, I am very pleased to report that EA’s stock has now spent the past five months trading in a manner that is exactly what we would hope to see falling such a massive decline… and though we still don’t know whether the next big move will be to the upside or the downside, I am encouraged by what we are seeing. For its fiscal 2019, EA recently reported revenues of $4.95 billion and net income of $1.0 billion, or $3.33 per share, as compared to revenues of $5.15 billion and net income of $1.0 billion, or $3.34 per share, in fiscal 2018. Also with patience, EA is a strong buy under $94 and a buy under $105.

First Solar

Yep – First Solar’s stocks is also showing some surprisingly good relative strength these days, especially given all the action on the trade war front! For the company’s first quarter, First Solar reported revenues of $532 million and a net loss of $67.6 million, or $0.64 per share, as compared to revenues of $691.2 million and net income of $52.1 million, or $0.49 per share, in last year’s first quarter. Though both Portfolios already have sizable positions in the stock, I am adding a few more shares to the Model this month in response to the good relative strength (but am not buying any in the Aggressive so as to not increase our margin debit at this point in time). FSLR remains a strong buy under $55 and a buy under $65.


Though Illumina’s stock is admittedly down sharply from where it was when last month’s issue went to press, as you can see in the chart to the right, it is another stock that appears to be undergoing “consolidation” when looked at on a longer-term basis, and, as you can probably guess, I will be thrilled if the stock can spend another two or three months bouncing back and forth between $290 and $330 to help set the stage for the next run to the upside. For its first quarter, Illumina reported revenues of $667 million and net income of $233 million, or $1.57 per share, as compared to revenues of $628 million and net income of $208 million, or $1.41 per share, a year ago. ILMN is now a strong buy under $290 and a buy under $320.


Ugh – there’s no denying that the chart to the left is clearly showing a stock that is “under pressure,” and while I continue to find the stock attractive on a longer-term basis, I will be the first to admit that if the stock doesn’t find some traction soon, it could be headed back to the teens in a hurry (and, consequently, I am moving a small portion of our position into the “sure thing” Celgene this month as a precaution). For its first quarter, Luminex reported revenues of $82.4 million and net income of just under $3 million, or $0.07 per share, as compared to revenues of $82.7 million and net income of $13.4 million, or $0.30 per share, in last year’s first quarter. LMNX is now considered a strong buy under $19 and a buy under $24.


Though it remains to be seen how much mileage (beyond the obvious 500, of course!) MannKind might get out of its sponsorship of Conor Daly in next weekend’s Indy 500, I hope you will tune-in to watch – not only will it be exciting if Conor can make a race of it, there may or may not be “human interest” stories shown during the race, and if he happens to be featured, it will be a nice bonus for us! As mentioned above, I want to encourage you to do whatever you need to do in order to feel comfortable with your MannKind position as a long-term investment (again, Catasys may be a nice alternative for “speculative” money), and then sit back and enjoy the ride. MNKD remains a strong buy under $5 and a buy under $10.

1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
Antwort auf Beitrag Nr.: 60.709.586 von Magnetfeldfredy am 31.05.19 19:14:49Der Letzte Satz ist der Beste!:laugh:
Stimmt. Und meine Hoffnung lebt weiter auf steigende nrx und refills
Wo exakt steckt hier der wurm


Versicherungen die nicht zahlen

Warum geht es nicht aufwärts mit den zahlen

Ich verstehe es nicht mehr

Oder wirkt es nicht
:keks:Nun so gut, Afrezza wurde in Brasilien zugelassen! Der Vertrieb soll mit dem 4.Quartal beginnen.
Hoffen wir, dass nun die Verkaufszahlen etwas oder sogar "noch mehr" steigen werden.
Die Hoffnung stirbt zuletzt. Jedenfalls mal eine sehr gute Nachricht.;):D
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
Hier offiziell, meiner Meinung nach sehr wichtig, da ein großer weltweiter Vertriebspartner Brasilien mit 12 Millionen Diabetikern als sehr significant einstufen könnte:

Afrezza® (insulin human) Inhalation Powder Approved in Brazil
GlobeNewswire•June 3, 2019

Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. The innovative delivery system reduces injections while improving glycemic control in adult patients with diabetes

WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil, June 03, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) and BIOMM SA (BIOM3.SA) today announced that Afrezza® (insulin human) Inhalation Powder, an ultra rapid-acting mealtime insulin to improve glycemic control in adult patients with diabetes mellitus, has been registered by the Brazilian Health Regulatory Agency (ANVISA). The commercialization of Afrezza in Brazil is expected to begin in the fourth quarter this year, subject to the pricing registration process by Câmara de Regulação do Mercado de Medicamentos (CMED).

“The regulatory approval of Afrezza in Brazil is an important milestone for MannKind and our partner Biomm. It not only represents our first international approval of Afrezza, but more importantly, we now have the opportunity to bring a novel mealtime insulin therapy to patients in a country with one of the highest prevalence of diabetes in the world, according to the International Diabetes Federation,” said Michael Castagna, Chief Executive Officer of MannKind Corporation.

Afrezza is an ultra rapid-acting orally inhaled insulin therapy indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered using a small, discreet and easy-to-use inhaler. Administered at the start of a meal, Afrezza dissolves rapidly upon inhalation to the deep lung and passes quickly into the bloodstream (in less than one minute). Glucose-lowering effects are achieved within minutes of administration, and clinical data with Afrezza demonstrates proven efficacy and safety in the treatment of both type 1 and type 2 diabetes.

“Insulin was first isolated and purified for clinical use in 1923 and now, almost 100 years later, we are excited that patients in Brazil are expected to soon have access to Afrezza, the only non-injectable oral insulin available in the market,” said Heraldo Marchezini, President Director/CEO of Biomm SA. “We believe that Afrezza, with its distinct time-action profile and route of administration, will address many of the unmet needs for mealtime insulin therapy and has the potential to change the way that diabetes is treated. As a pioneering biotechnology company, we are proud to leverage our portfolio of diabetes products and offer another option to treat the significant and growing numbers of patients with diabetes in Brazil.”

Currently, diabetes mellitus affects 425 million adults worldwide, including more than 12 million in Brazil, according to the International Diabetes Federation. Diabetes mellitus is characterized by the body's inability to regulate levels of blood glucose properly. Insulin, a hormone produced by the pancreas, normally regulates the body's glucose levels, but in people with diabetes mellitus insufficient levels of insulin are produced or the body fails to respond adequately to the insulin it produces.

MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes, and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing and research facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Biomm's mission is to develop, produce and market global competitive biomedicines with quality and accessibility. The company's focus is developing biological products, aiming to guarantee national self-sufficiency. Due to its innovator DNA, the company is pioneer in biotechnological drugs in Brazil. Founded in 2002, Biomm’s headquarters and factory are in Nova Lima (MG), with capacity to produce 20 million vials of insulin per year, based on advanced and innovative technologies that guarantee the medicines quality. The company is listed on the Brazilian stock exchange (BIOM3.SA). For further information access www.biomm.com.

This press release contains forward-looking statements that involve risks and uncertainties. Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s and Biomm’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks detailed in MannKind’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and neither MannKind nor Biomm undertakes any obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

MannKind Corporation
Rose Alinaya
Investor Relations

Biomm S/A
Bruna Sales - +55 11 3147 7423 | c: +55 11 94836 6956

Raquel Tomacelli - +55 11 3147-7906 | +55 11 98048-8022

Nancy Campos - + 55 (11) 3147-7900| + 55 11 97574-9149

Antwort auf Beitrag Nr.: 60.721.710 von peppino23 am 03.06.19 14:38:46Genial wo hast du das finden können
425 Millionen Diabetiker, 1 % Anteil an Afrezza, was in 5-10 Jahren durchaus denkbar ist dann sind wir Millionäre, 4 Millionen mal 2000 US Dollar pro Jahr = 8 Milliarden Umsatz x Faktor 10 = Bewertung 80 Milliarden US Dollar = Kurswert 80 US Dollar pro Mannkind Aktie!:eek::D
Träumen darf mann doch!:D
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.

Beitrag zu dieser Diskussion schreiben